<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474717</url>
  </required_header>
  <id_info>
    <org_study_id>15.06.2020</org_study_id>
    <nct_id>NCT04474717</nct_id>
  </id_info>
  <brief_title>Chronic Obstructive Pulmonary Disease in Combination With Atherosclerosis (Clinical and Biochemical Study)</brief_title>
  <official_title>Clinical and Biochemical Assessment of the Course of Chronic Obstructive Pulmonary Disease in Combination With Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryazan State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryazan State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      one-centered, open, non-randomized, controlled clinical trial will focus on a comprehensive
      study of the clinical, functional and molecular biochemical characteristics of the natural
      course of COPD in combination with peripheral atherosclerosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Risk factors, chronic respiratory symptoms and respiratory function in the natural history of
      COPD will be monitored. In a group of patients with a comorbid course of COPD and
      atherosclerosis, systemic inflammation and its molecular mechanisms will be investigated.
      Also in this group, the role of non-coding miRNAs will be analyzed. The study also includes
      an analysis of the clinical and biochemical COPD phenotype with systemic inflammation and
      comorbidity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>12 months</time_frame>
    <description>the number of deaths from cardiovascular causes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lung function</measure>
    <time_frame>12 months</time_frame>
    <description>progression of decreased lung function (FEV1%) according to spirometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>frequency of exacerbations of COPD (number of cases per year)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>markers of inflammation</measure>
    <time_frame>12 months</time_frame>
    <description>biochemical markers of inflammation (IL-6, pg/ml; IL-8,pg/ml;TNF,pg/ml)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>The natural history of COPD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring risk factors, chronic respiratory symptoms and respiratory function in the natural history of chronic obstructive pulmonary disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study of systemic inflammation and molecular mechanisms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study of systemic inflammation and molecular mechanisms underlying the comorbid course of COPD and atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-coding miRNAs</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Investigation of the role of non-coding miRNAs in the epigenetic regulation of signaling pathways involved in the pathogenesis of COPD and atherosclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exhaled breath condensate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A study of the clinical and biochemical COPD phenotype with systemic inflammation and comorbidity</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Breath Condensate Collection</intervention_name>
    <description>Breath Condensate Collection</description>
    <arm_group_label>Exhaled breath condensate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Real-time PCR</intervention_name>
    <description>Real-time PCR</description>
    <arm_group_label>non-coding miRNAs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>clinical examination, spirometry</intervention_name>
    <description>spirometry</description>
    <arm_group_label>The natural history of COPD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood monocyte assay</intervention_name>
    <description>study of blood monocytes in the laboratory of cell technology</description>
    <arm_group_label>Study of systemic inflammation and molecular mechanisms</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A significant diagnosis of COPD, confirmed by spirometry criteria, typical clinical
             presentation.

          2. A significant diagnosis of peripheral atherosclerosis

          3. The high level of adherence to treatment

          4. Signed informed agreement

        Exclusion Criteria:

          1. The presence of other chronic respiratory diseases in the patient, including bronchial
             asthma

          2. Known oncological diseases of any localization

          3. HIV infection and other immunodeficiency conditions

          4. Inability to understand and comply with the requirements of the research protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stanislav Kotlyarov, PhD</last_name>
    <phone>+79065410775</phone>
    <email>SKMR1@yandex.ru</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>peripheral atherosclerosis</keyword>
  <keyword>comorbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

